SCHEMBL523059

SCHEMBL523059

Clc1ccc(C2=NCCN2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.96
RECQL P46063 1/20 0.96
NISCH Q9Y2I1 12/20 0.66
TOP2A P11388 2/20 0.61
TOP2B Q02880 2/20 0.61
HTR1D P28221 1/20 0.59
ADRA1A P35348 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8188355 0.98 LMNA (0.92) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL5476725 0.89 NISCH (0.79) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL26126801 0.84 NISCH (0.76) LMNARECQLNISCH
SCHEMBL8206164 0.83 LMNA (0.68) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL26123421 0.83 LMNA (0.68) LMNARECQLNISCH
SCHEMBL8202723 0.82 NISCH (0.75) LMNARECQLNISCH
SCHEMBL8188588 0.81 LMNA (0.63) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL8196146 0.79 NISCH (0.88) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL1209074 0.79 NISCH (0.66) LMNARECQLNISCHTOP2ATOP2B
SCHEMBL8141372 0.79 NISCH (1.00) LMNARECQLNISCHTOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5112715-A Toner compositions containing a multi-purpose additive EASTMAN KODAK COMPANY (US) 1992-05-12 US claimed
US-5102765-A Toner compositions containing 2-imidazolines, imidazoles or benzimidazoles as charge control agents EASTMAN KODAK COMPANY (US) 1992-04-07 US claimed
JP-4188119-A None JP disclosed
EP-2421836-A1 2-ARYL IMIDAZOLINE DERIVATIVES MSD K.K. (JP) 2012-02-29 EP disclosed
US-20120029041-A1 2-ARYL IMIDAZOLINE DERIVATIVES MSD K.K. (JP) 2012-02-02 US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2010123150-A1 2-ARYL IMIDAZOLINE DERIVATIVES BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-28 WO disclosed
EP-1287055-B9 POWDER COMPOSITIONS FOR HEAT SENSITIVE SUBSTRATES VALSPAR SOURCING INC (US) 2010-06-02 EP disclosed
EP-1287055-B1 POWDER COMPOSITIONS FOR HEAT SENSITIVE SUBSTRATES VALSPAR SOURCING INC (US) 2010-01-06 EP disclosed
EP-1753727-A1 NOVEL CIS-IMIDAZOLINES F.HOFFMANN-LA ROCHE AG (CH) 2007-02-21 EP disclosed
WO-2005110996-A1 NOVEL CIS-IMIDAZOLINES F.HOFFMANN-LA ROCHE AG (CH) 2005-11-24 WO disclosed
EP-0331507-B1 POLYVINYL CHLORIDE PLASTISOL COMPOSITION ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) 1993-05-19 EP disclosed
US-5154858-A Mixture of 2-(p-chlorophenyl)imidazoline and a compound having an electron donative and an electron attractive group MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1992-10-13 US disclosed
JP-H04188119-A NONLINEAR OPTICAL MATERIAL MATSUSHITA ELECTRIC IND CO LTD 1992-07-06 JP disclosed
EP-0487019-A2 Use of a nonlinear optical compound MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1992-05-27 EP disclosed
US-5112715-A Toner compositions containing a multi-purpose additive EASTMAN KODAK COMPANY (US) 1992-05-12 US disclosed
US-5102765-A Toner compositions containing 2-imidazolines, imidazoles or benzimidazoles as charge control agents EASTMAN KODAK COMPANY (US) 1992-04-07 US disclosed
US-4977201-A Blended with modified epoxy resin, blocked isocyanate, latent curing for resin as tackifier, automobile undercoatings ASAHI DENKA KOGYO K.K. (JP) 1990-12-11 US disclosed
EP-0331507-A1 Polyvinyl chloride plastisol composition ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) 1989-09-06 EP disclosed
US-3932450-A Intermediates in the preparation of imidazo(2,1-alpha)isoindoles SANDOZ, INC. (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 LMNA 3427/4885RECQL 1894/4885NISCH 3272/4885
US-20120029041-A1 2-ARYL IMIDAZOLINE DERIVATIVES CLIC1, NAT1, NMRAL1 LMNA 1996/4885RECQL 1868/4885NISCH 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.